Abstract Number: 0416 • ACR Convergence 2021
Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…Abstract Number: 0421 • ACR Convergence 2021
Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) negative granulomatosis with polyangiitis (GPA) is a challenging diagnosis. There is paucity of literature regarding the clinical course of ANCA-negative…Abstract Number: 0431 • ACR Convergence 2021
Clinical Characteristics and Outcomes of ANCA-Associated and Non Immune-Mediated Hypertrophic Pachymeningitis: A Comparative Study
Background/Purpose: Hypertrophic pachymeningitis (HP) is an infrequent manifestation in autoimmune and non-autoimmune conditions. The differences in clinical characteristics and outcomes of ANCA-associated and non-immune-mediated HP…Abstract Number: 0436 • ACR Convergence 2021
Ocular and Orbital Manifestations of Granulomatosis with Polyangiitis: A Systematic Review of Published Cases
Background/Purpose: Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s Granulomatosis, is a systemic autoimmune condition caused by granulomatous inflammation of small and medium arteries, arterioles…Abstract Number: 0525 • ACR Convergence 2021
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…Abstract Number: 1438 • ACR Convergence 2020
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)
Background/Purpose: Rituximab (RTX), an anti-CD20 chimeric monoclonal antibody, has been shown to be an effective maintenance therapy for granulomatosis with polyangitiis (GPA) and microscopic polyangiitis…Abstract Number: 1524 • ACR Convergence 2020
Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice
Background/Purpose: To explore the pathogenic potential of lymphocytes in systemic sclerosis (SSc) and granulomatosis with polyangiitis (GPA), a humanized mouse model was generated by transferring…Abstract Number: 2048 • ACR Convergence 2020
Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or…Abstract Number: 2049 • ACR Convergence 2020
Nasal Bacteria Associated with Disease Activity and ANCA Levels in Granulomatosis with Polyangiitis
Background/Purpose: Nasal bacteria have been linked to disease activity in granulomatosis with polyangiitis (GPA) with most studies focused on Staphylococcus aureus. Our previous study identified…Abstract Number: 2050 • ACR Convergence 2020
Autoantibodies Targeting Complement Receptors C3aR and C5aR1 Are Decreased in ANCA-associated Vasculitis and Correlate with a Higher Relapse Rate
Background/Purpose: Activation of the alternative and common terminal complement pathways has been shown in ANCA-associated vasculitis (AAV). Circulating titers of the anaphylatoxin C5a are increased…Abstract Number: 2051 • ACR Convergence 2020
Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database
Background/Purpose: The clinical picture at onset and evolution of localized forms of granulomatosis with polyangiitis (L-GPA) have already been investigated but, to our knowledge, have…Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…Abstract Number: 1032 • ACR Convergence 2020
Epidemiology and Geographic Evaluation of ANCA-associated Vasculitis (AAV) at a Rural Academic Health Center Utilizing an Electronic Health Record (EHR)
Background/Purpose: ANCA-associated vasculitis has a reported prevalence ranging from 3.2 to 9.1 cases per 100,000 individuals, but little is known of geographic variations. The aim of…Abstract Number: 1417 • ACR Convergence 2020
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…Abstract Number: 1418 • ACR Convergence 2020
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a rare and life-threatening autoimmune disease. Due to the extremely low prevalence of GPA, monitoring of clinical characteristics and…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »
